SCH 23390 (CAS 125941-87-9)

SCH-23390 (SCH) is a highly selective dopamine D1 receptor antagonist with a rich history of over 30 years in scientific research. Renowned as one of the most extensively investigated dopamine antagonists, it has played a pivotal role in numerous studies exploring the impact of dopamine in the brain and its behavioral effects. By delving into the central nervous system, SCH has contributed to our understanding of dopamine′s influence on various diseases and conditions. SCH-23390 exhibits a diverse range of biochemical and physiological effects. These include inhibiting dopamine reuptake and release, as well as suppressing the activity of phosphodiesterase enzymes and adenylyl cyclase. Through studies utilizing SCH-23390, researchers have investigated the effects of dopamine on behavior, cognition, and neurophysiology. Moreover, they have examined its potential implications in disorders such as Parkinson′s disease, Huntington′s disease, schizophrenia, and depression. Furthermore, SCH-23390 has shed light on the impact of dopamine on essential biochemical processes, encompassing gene expression, signal transduction, and neurotransmitter release. Studies have encompassed various cell types, from neurons to glial cells, to comprehensively explore the effects of SCH-23390. By binding to the dopamine D1 receptor, which belongs to the G-protein coupled receptor family, SCH-23390 elicits a reduction in receptor activity, ultimately leading to diminished dopamine signaling.